{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"The primary objective of this prospective, phase II trial was to obtain an OS rate of \\>60% at 1 year in patients undergoing a 2 step HSCT from an HLA compatible family donor. The \\>60% threshold was selected as a composite efficacy measure as patients with any hematologic diagnosis, stage of disease, or age as old as 65 years were eligible for this treatment protocol.","groups":[{"description":"Matched Sibling Allogeneic Transplantation\n\nMatched Sibling Allogeneic Transplantation: Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization","id":"OG000","title":"Allogeneic Transplantation"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 Year after transplant","title":"Number of Patients With Overall Survival","type":"PRIMARY","unitOfMeasure":"Participants"}